- AU$55.38bn
- AU$72.46bn
- $15.56bn
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australia's CSL plans to invest $1.5 billion in US plasma therapy expansion (updated)
Australia's CSL plans to invest $1.5 billion in US plasma therapy expansion
Advisory: Alerts incorrectly tagged to Australia's CSL withdrawn
Brief: CSL Ltd Sees High Single-Digit NPAT Growth Beyond FY26
Australia's CSL up as Morgan Stanley remains positive on plasma division
Australia's CSL set for worst week in 2 months on delaying spin-off
Brief: CSL Says CSL Seqirus & Vaccine Industrial Sign Landmark MoU With Ministry Of Health
Australia's CSL unit partners with Saudi Arabia on local flu vaccine manufacturing (updated)
Australia's CSL's vaccine unit to collaborate on flu vaccines with Saudi Arabia
Australian shares close at two-week low as inflation spike sinks rate cut hopes
Street View: US vaccine fatigue plaguing Australia's CSL; stock falls
Australia's CSL extends losses to hit lowest since 2018
Australia's CSL tanks to nearly 7-year low on spin-off delay, outlook downgrade
Australian healthcare stocks dive after CSL delays spinoff
Australia shares retreat as CSL drags on delaying vaccine division spinoff
Australia's CSL slumps to near 7-year low on delaying vaccine division spinoff
Australia's CSL delays vaccine division spin-off amid US market volatility (updated)
Brief: CSL Says No Longer Targeting Completion Of Demerger In FY2026